

# Medicine: dabrafenib (brand name: Tafinlar®) for treating melanoma with a BRAF V600 mutation after surgery

Novartis Pharmaceuticals UK Ltd

## What is dabrafenib used for?

Dabrafenib was considered for use in patients with melanoma, which is a type of skin cancer. It is used to treat adult patients with advanced melanoma who have had surgery to remove the melanoma that had previously spread to the lymph nodes (stage 3 melanoma). Dabrafenib is used alongside another medicine called trametinib in patients whose cancer cells have a genetic change (mutation) called BRAF V600.

## How does dabrafenib work?

Dabrafenib works by blocking a protein called BRAF, which helps cells to multiply. In melanoma cells with the BRAF V600 mutation, BRAF is overactive causing the cells to multiply in an uncontrolled way. By blocking BRAF V600, dabrafenib helps slow down the growth and development of the cancer cells.

### What has SMC said?

SMC has accepted dabrafenib for the treatment of patients with melanoma, as described above.



## Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.

- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration, applying extra flexibility because dabrafenib is a medicine for a rare condition, and after the company applied a confidential discount to the cost of the medicine, SMC was able to accept it as a possible treatment within NHSScotland.

### What does SMC's decision mean for me?

If your healthcare professional thinks that dabrafenib for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland. For further information see:

Medicines in Scotland: What's the right treatment for me?

[www.healthcareimprovementscotland.org/medicinesbooklet.aspx](http://www.healthcareimprovementscotland.org/medicinesbooklet.aspx)



### More information

The organisations below can provide more information and support for people with melanoma and their families. SMC is not responsible for the content of any information provided by external organisations.

#### Melanoma Action and Support Scotland (MASScot)

 <http://www.masscot.org.uk>

 0141 946 2017

#### Melanoma UK

 <https://www.melanomauk.org.uk/>

 0808 171 2455

You can find out more about dabrafenib in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.

 <http://www.ema.europa.eu>

**Date advice published:** 11 February 2019

**SMC No:** (SMC2131)